Hexafluoropropylene (C3F8), Sulphur hexafluoride (SF6), Vitreomacular traction, Vitrectomy.


Background: To study the efficacy of a single 0.3ml of C3F8 injection for the treatment of symptomatic VMT. Methods: In this retrospective interventional study a total of nine patients were recruited. The mean age was 67 years. Patients had a follow up at one week and four weeks post injections. VMT status was confirmed on repeat Oct scan. Results: There was a complete release of VMT In 4 patients after one week and further release of VMT was observed in two more patients after four weeks. Hence six out of nine patients had complete resolution of pathology following C3F8 injection. Conclusion: Intravitreal C3F8 is a cheaper and safer option for the treatment of vitreomacular traction as compared to pars plana vitrectomy or Ocriplasmin.


Reese AB, Jones IS, Cooper WC. Vitreomacular traction syndrome confirmed histologically. Am J Ophthalmol 1970;69(6):975–7.

Steel DHW, Lotery AJ. Idiopathic vitreomacular traction and macular hole: a comprehensive review of pathophysiology, diagnosis, and treatment. Eye (Lond) 2013;27(Suppl 1):S1–21.

Javed RM, Khan AA, Tayyab H, Chaudhry N. SF6 Assisted Pneumatic Vitreolysis in Cases of Vitreomacular Traction Syndrome. Pak J Ophthalmol 2018;34(3):139–44.

Jackson TL, Nicod E, Angelis A, Grimaccia F, Prevost AT, Simpson ARH, et al. Pars plana vitrectomy for vitreomacular traction syndrome: A systematic review and metaanalysis of safety and efficacy. Retina 2013;33(10):2012–7.

Do DV, Cho M, Nguyen QD, Shah SM, Handa JT, Campochiaro PA, et al. The impact of optical coherence tomography on surgical decision making in epiretinal membrane and vitreomacular traction. Trans Am Ophthalmol Soc 2006;104:161–6.

Bottós J, Elizalde J, Arevalo JF, Rodrigues EB, Maia M. Vitreomacular Traction Syndrome. J Ophthalmic Vis Res 2012;7(2):148–61.

Wendel RT, Patel AC, Kelly NE, Salzano TC, Wells JW, Novack GD. Vitreous Surgery for Macular Holes. Ophthalmology 1993;100(11):1671–6.

Stein JD, Zacks DN, Grossman D, Grabe H, Johnson MW, Sloan FA. Adverse Events After Pars Plana Vitrectomy Among Medicare Beneficiaries. Arch Ophthalmol 2009;127(12):1656–63.

Smiddy William E. Patient Selection for Ocriplasmin Treatment of Patients with VMT: The honeymoon is over, but the marriage is stable. Retin Physician 2015;12:19–20.

Quezada Ruiz C, Pieramici DJ, Nasir M, Rabena M, Avery RL. Severe acute vision loss, dyschromatopsia, and changes in the ellipsoid zone on sd-oct associated with intravitreal ocriplasmin injection. Retinal Cases Brief Rep 2015;9(2):145–8.

Hecht I, Mimouni M, Blumenthal EZ, Barak Y, Charles S. Sulfur Hexafluoride (SF 6 ) versus Perfluoropropane (C 3 F 8 ) in the Intraoperative Management of Macular Holes: A Systematic Review and Meta-Analysis. J Ophthalmol 2019;2019:1820850.

Team RR. Pneumatic Vitreolysis: The Little Bubble that Could. Interview with Clement Chan, MD [Internet]. Retina Round Up. 2017 [cited 2022 Oct]. Available from: https://retinaroundup.com/2017/10/20/pneumatic-vitreolysis-the-little-bubble-that-could-interview-with-clement-chan-md/

Day S, Martinez JA, Nixon PA, Levitan M, Dooner JW, Wong RW, et al. Intravitreal sulfur hexafluoride injection for the treatment of vitreomacular traction syndrome, National Institutes of Health. Retina 2016;36(4):733–7.

Chan CK, Wessels IF, Friedrichsen EJ. Treatment of Idiopathic Macular Holes by Induced Posterior Vitreous Detachment. Ophthalmology 1995;102(5):757–67.

Claus MG, Feron E, Veckeneer M. Pneumatic release of focal vitreomacular traction. Eye (Lond) 2017;31(3):411–6.

Mori K, Saito S, Gehlbach PL, Yoneya S. Treatment of stage 2 macular hole by intravitreous injection of expansile gas and induction of posterior vitreous detachment. Ophthalmology 2007;114(1):127–33.

Stalmans P, Benz MS, Gandorfer A, Kampik A, Girach A, Pakola S, et al. Enzymatic Vitreolysis with Ocriplasmin for Vitreomacular Traction and Macular Holes. N Engl J Med 2012;367(7):606–15.

Jorge R, Costa RA, Cardillo JA, Uno F, Bonomo PP, Farah ME. Optical coherence tomography evaluation of idiopathic macular hole treatment by gas-assisted posterior vitreous detachment. Am J Ophthalmol 2006;142(5):869–71.

Primavera V, Agea L, Cicinelli MV, Centoducati T, Alessio G, Querques G. Intravitreal injection of air for the treatment of vitreomacular traction. Retin Cases Brief Rep 2020;14(2):141–5.

Gonzalez MA, Flynn HW, Bokman CM, Feuer W, Smiddy WE. Outcomes of Pars Plana Vitrectomy for Patients with Vitreomacular Traction. Ophthalmic Surg Lasers Imaging Retina 2015;46(7):708–14.

Steinle N, Dhoot D, Pieramici DJ, See RF, Castellarin A, Couvillion S, et al. Comparison of Three Non-surgical Treatments for Vitreomacular Traction (VMT). Invest Ophthalmol Vis Sci. 2016;57(12).

Knudsen VM, Kozak I. A retrospective study of a single practice use of ocriplasmin in the treatment of vitreomacular traction. Saudi J Ophthalmol 2014;28(2):139–44.

Khan MA, Haller JA. Ocriplasmin for Treatment of Vitreomacular Traction: An Update. Ophthalmol Ther 2016;5(2):147–59.

Steinle NC, Dhoot DS, Ruiz CQ, Castellarin AA, Pieramici DJ, See RF, et al. Treatment of vitreomacular traction with intravitreal perfluoropropane (C3F8) injection. Retina 2017;37(4):643–50.

Additional Files